Skip to main content
. 2016 Jun 17;9:135–142. doi: 10.2147/CCID.S91691

Table 1.

Comparison of biologics and biosimilars

Biologics Biosimilars
Manufacturing Heterogeneous product Heterogeneous product
Immunogenicity Potential risk Potential risk
Regulation BLA aBLA
Indications Only for those approved by the US Food and Drug Administration All indications of the original biologics
Potential for patent licensing Yes No
Potential for exclusivity period Yes, 12 years No
Potential for interchangeability No Yes

Note: Data from Blackstone and Fuhr5 and Camacho et al.9

Abbreviations: BLA, biologics license application; aBLA, abbreviated biologics license application.